Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BNT162b2 Vaccine · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| BNT162b2 Vaccine | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| 5-11 Years (Higher-Risk Individuals) | EXPERIMENTAL | BNT162b2 (2025/2026 formulation) |
| Group 1: 18 through 64 years of age (higher-risk individuals) | EXPERIMENTAL | Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1 |
| Group 2: 65 years of age and older | EXPERIMENTAL | Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1 |
| Group 3: 12 through 64 years of age (higher-risk individuals) | EXPERIMENTAL | Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1 |
| Group 4: 65 years of age and older | EXPERIMENTAL | Participants will receive BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) 30 µg at Visit 1 |
| Name | Type | Description |
|---|---|---|
| BNT162b2 Vaccine | BIOLOGICAL | Single dose |
| Placebo | BIOLOGICAL | Single dose |
| BNT162b2 (2025/2026 formulation) | BIOLOGICAL | BNT162b2 (formulation targeting the 2025/2026 recommended SARS-CoV-2 strain) |
| BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) | BIOLOGICAL | BNT162b2 monovalent (2025/2026 recommended SARS-CoV-2 strain) |
Key Inclusion Criteria * People who are between 50 and 64 years old at their first appointment. * People who are healthy and, based on their medical history and a doctor's judgment, are considered suitable to join the study. Key Exclusion Criteria * People who had COVID-19 in the past 3 months (9...
BNT162b2 is an investigational RNA-based vaccine being studied for the prevention of SARS-CoV-2 infection and COVID-19. It is being evaluated in healthy participants, including pregnant women, to assess safety, tolerability, and immunogenicity against COVID-19 and its variants.
BNT162b2 is being developed by BioNTech SE, a biotechnology company traded on the Nasdaq under the ticker BNTX. The vaccine is currently in clinical development and has not been approved for use.
BNT162b2 is in Phase 2 clinical development. It is an investigational vaccine and has not received regulatory approval. The most recent trials are Phase 2 studies evaluating safety and immunogenicity in healthy participants, including pregnant women.
BNT162b2 has been studied in several clinical trials, including NCT04713553, a Phase 3 study of multiple production lots and dose levels, and NCT04754594, a Phase 2 study in pregnant women. Other Phase 2 trials include NCT05004181 and NCT05997290, which evaluate safety and immunogenicity against SARS-CoV-2 variants.
Yes, BNT162b2 is also known as BNT162b2 Vaccine. The drug is an RNA-based vaccine candidate developed by BioNTech SE for the prevention of COVID-19 and SARS-CoV-2 infection.